|
Oct 8
|
TFF Pharmaceuticals (TFFP) Upgraded to Strong Buy: Here's Why
|
|
Jun 26
|
TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities
|
|
Jun 24
|
TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for the Prevention of Lung Transplant Rejection
|
|
May 15
|
TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection
|
|
May 14
|
TFF Pharmaceuticals, Inc. (TFFP) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 14
|
TFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
|
|
May 1
|
TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering
|
|
Apr 30
|
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
|
|
Apr 29
|
TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting
|
|
Apr 15
|
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
|
|
Apr 1
|
TFF Pharmaceuticals Full Year 2023 Earnings: Misses Expectations
|
|
Mar 28
|
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 27
|
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs
|
|
Mar 25
|
TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation...
|
|
Mar 22
|
TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
|
|
Mar 20
|
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
|
|
Mar 20
|
TFF Pharmaceuticals Announces Update on Clinical Programs
|
|
Mar 14
|
TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024
|
|
Jan 9
|
TFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting
|
|
Dec 19
|
TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC
|